InsightAce Analytic Pvt. Ltd. has released a market assessment report on the Global Nuclear Pharmacy Market. The market is valued at $5.20 billion in 2022 and is expected to reach $12.85 billion by 2031, with a CAGR of 10.6% during the forecast period of 2023-2031. The rising awareness of the potential effects of early diagnosis and treatment of chronic illnesses is driving the growth of the nuclear pharmacy market. Advancements in nuclear imaging technology, such as PET/PET-CT and SPECT-CT systems, are also contributing to market growth. The need for nuclear medical procedures and radiopharmaceuticals, driven by the prevalence of chronic diseases, is another driving factor. However, the nuclear pharmacy sector faces challenges such as the high cost of specialized machinery and infrastructure, as well as supply chain disruptions. The North America market is expected to register a major market share and grow at a high CAGR, driven by the booming healthcare sector and rising cancer rates in the region. In Europe, the demand for precise diagnosis and treatment planning has led to an increase in the use of nuclear medicine operations.
Sat, 19 Aug 2023 01:48:30 GMT | Digital Journal